3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
13
Gastrointestinal
3
Gynecologic
2
Head & Neck
1
Genitourinary
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Breast Neoplasms
196
Triple Negative Breast Neoplasms
26
Neoplasm Metastasis
18
Breast Neoplasms, Male
13
Ovarian Neoplasms
9
Inflammatory Breast Neoplasms
9
Pancreatic Neoplasms
8
Neoplasms
7
Colorectal Neoplasms
7
Carcinoma, Non-Small-Cell Lung
6
Stomach Neoplasms
5
Prostatic Neoplasms
4
Lung Neoplasms
4
Endometrial Neoplasms
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Sarcoma
2
Recurrence
2
Multiple Myeloma
2
Lymphedema
2
Hematologic Neoplasms
2
Esophageal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Ovarian Epithelial
2
Brain Neoplasms
2
Uterine Neoplasms
1
Urologic Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Interventions
pembrolizumab
14
Gemcitabine
8
Docetaxel
7
Nivolumab
6
durvalumab
5
Cyclophosphamide
5
130-nm albumin-bound paclitaxel
5
atezolizumab
4
Magnetic Resonance Spectroscopy
4
Irinotecan
4
sargramostim
3
aldesleukin
3
Specimen Handling
3
Radiotherapy
3
Paclitaxel
3
Ipilimumab
3
Fulvestrant
3
Cisplatin
3
Carboplatin
3
venetoclax
2
temsirolimus
2
talazoparib
2
spartalizumab
2
olaparib
2
liposomal doxorubicin
2
fludarabine phosphate
2
cabozantinib
2
budigalimab
2
avelumab
2
Vinorelbine
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Small Cell Lung Carcinoma
×
Bevacizumab
×
Breast
×
Clear all
NCT02734004
2026-04-20
MEDIOLA
AstraZeneca
Phase 1/2
Active not recruiting
264 enrolled
32 charts